Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

See Locations Near You

Summary

This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
Patient has good performance status (ECOG 0 or 1)

Exclusion Criteria:

Prior treatment with either SU011248 or capecitabine.
Hypertension that cannot be controlled by medications

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

77

Study ID:

NCT00618124

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Pfizer Investigational Site
Indianapolis Indiana, 46202, United States
Pfizer Investigational Site
Albuqurque New Mexico, 87131, United States
Pfizer Investigational Site
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

77

Study ID:

NCT00618124

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider